Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 02, 2021 | June 04, 2021 |
| Sio Gene Therapies Inc.AXON · Entity 130622 | Director | April 28, 2017 | May 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date June 02, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 91,395 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 22,766 · Balance 91,395 F1: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
Sio Gene Therapies Inc.
Report date April 28, 2017 · Filed May 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.24 · Expires 2027-04-28 | Direct | 27,000 |
Reported balance
After 2017-04-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-28 · Grant · Acquired 27,000 · Balance 27,000 F1: 100% of this option will vest one year after the date of grant. The option allows for early exercise, subject to the issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F2: Includes only options with the same termination date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this option will vest one year after the date of grant. The option allows for early exercise, subject to the issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
F2: Includes only options with the same termination date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2021 Filed Jun 4, 2021 20:16 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,766 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038213 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,395 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:32 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 11,350 | $10.06 | $114,181.00 |
DisclosureSEC source: 0001209191-20-036289 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,629 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.80 to $10.78, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 20:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034699 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,979 F1 · kind: The restricted stock, granted pursuant to the Director Compensation Policy effective May 2019, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,000 | $11.25 | $22,500.00 |
DisclosureSEC source: 0001209191-19-035513 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,259 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.37, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:15 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 22,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-033637 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,259 F1 · kind: The restricted stock, granted pursuant to the director compensation policy, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 21:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,000 | $14.41 | $28,820.00 |
DisclosureSEC source: 0001209191-19-017301 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,553 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.16 to $14.67, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 06, 2018 Filed Dec 10, 2018 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,000 | $12.47 | $24,940.00 |
DisclosureSEC source: 0001209191-18-061788 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,553 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 20:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,000 | $19.10 | $38,200.00 |
DisclosureSEC source: 0001209191-18-050031 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,553 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.90 to $19.26, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:26 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,000 | $17.62 | $35,240.00 |
DisclosureSEC source: 0001209191-18-036352 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,553 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.87, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 21:29 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 16,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035249 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,553 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 00:17 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,000 | $14.05 | $28,100.00 |
DisclosureSEC source: 0001209191-18-017511 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,330 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.98 to $14.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:14 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,900 | $16.48 | $31,312.00 |
DisclosureSEC source: 0001209191-17-064179 · doc4.xml · nonDerivative · entry 2 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,330 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · shares: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $17.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $17.09, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 04, 2017 Filed Dec 6, 2017 21:14 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 100 | $16.09 | $1,609.00 |
DisclosureSEC source: 0001209191-17-064179 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,230 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:40 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 2,000 | $16.15 | $32,300.00 |
DisclosureSEC source: 0001209191-17-051890 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,330 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.02 to $16.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:27 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,200 | $17.78 | $56,896.00 |
DisclosureSEC source: 0001209191-17-039167 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,330 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.61 to $18.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 31, 2017 Filed Jun 2, 2017 21:02 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-037354 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,530 F1 · kind: Issued pursuant to the Director Compensation Plan, effective as of January 2014. Read SEC document |
| April 28, 2017 Filed May 2, 2017 21:07 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $24.24 | $0.00 |
DisclosureSEC source: 0001209191-17-029474 · doc4.xml · derivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Shares · 27,000 shares Expires 2027-04-28 F1 · derivative.exercise_date: 100% of this option will vest one year after the date of grant. The option allows for early exercise, subject to the issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. F2 · balance_after: Includes only options with the same termination date. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 22:32 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,200 | $17.19 | $55,008.00 |
DisclosureSEC source: 0001209191-17-018896 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,905 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.99 to $17.43, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 23:57 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,200 | $15.68 | $50,176.00 |
DisclosureSEC source: 0001209191-16-154010 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,105 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $15.82, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 06, 2016 Filed Sep 7, 2016 23:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 3,200 | $13.72 | $43,904.00 |
DisclosureSEC source: 0001209191-16-140466 · doc4.xml · nonDerivative · entry 1 OLANOFF LAWRENCE S · CIK 0001224341 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,305 F1 · kind: This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and was effected to cover tax withholding obligations in connection with the vesting of the reporting person's director restricted stock awards. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.49 to $13.89, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.